Published in Drug Week, June 11th, 2004
These submissions mark the first time that health authorities will review data on a breast cancer therapy for use following treatment with tamoxifen in the extended adjuvant setting.
The filings comprise results of the independent landmark MA-17 study, which were published expeditiously by the New England Journal of Medicine in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.